| Utestående aktier | 59,074,391 shares |
| Insideraktier | 15 902 852 shares |
| Insynsägande | 26,92 % |
| Totalt antal insynspersoner | 26 |
Insider Sentiment Score
Insider sentiment score hittar de företag som köps av foretagsinsynspersoner.
Det är resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av insiderackumulation. Poängmodellen använder en kombination av nettoantalet insiders som köpt de föregående 90 dagarna, det totala antalet aktier som köpts i procent av aktiekapitalet och det totala antalet aktier som ägs av insiders. Siffran sträcker sig från 0 till 100, med högre siffror som indikerar en högre nivå av ackumulering för sina kamrater, och 50 är genomsnittet.
Uppdateringsfrekvens: Dagligen
Se Insiders Top Picks, som ger en lista över företag med högsta insiderackumulation.
Office Sentiment Score
Officersentiment Score hittar företag som köps av Corporate Officers.
Per definition Corporate Officers är Corporate Insiders, men till skillnad från vissa av de andra Insiders (10 % aktieägare och styrelseledamöter), arbetar ämbetsmän för företaget dagligen och de använder sina egna pengar när de handlar . (10 % aktieägare och styrelseledamöter är ofta fondförvaltare som förvaltar andras pengar.) Som sådan är insideraffärer som görs av tjänstemän mycket mer betydelsefulla och bör behandlas på lämpligt sätt.
Liksom Insider Sentiment Score är Officer Sentiment Score resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av officersackumulering.
Uppdateringsfrekvens: Dagligen
Se insiderns bästa val, vilket ger en lista över företag med högsta insider sentiment.
Viktiga insidernyckeltal
Denna kort visar hur företaget rankas längs olika insidernyckeltal. Procenttilrankningen visar hur detta företag jämförs med andra företag på USA-marknaden. Högre rankingar indikerar bättre situationer.
Till exempel anses det allmänt att insiderköp är en positiv indikator, så företag med mer insiderköp skulle rankas högre än företag med mindre insiderköp (eller til och med insiderförsäljning).
Procent av flytande köpta av insiders (ranking)
0.000 %( )
5673 out of 11226Procentandelen av aktier köpta av insiders är det totala antalet aktier som köpts av insiders minus det totala antalet aktier som sålts av insiders under de senaste 90 dagarna, dividerat med det totala antalet aktier och multiplicerat med 100.
Insiderhandelsdiagram
Cullinan Therapeutics, Inc. insideraffärer visas i följande diagram. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. I allmänhet är det i allmänhet olagligt för insiders att göra affärer i sina företag baserat på väsentlig, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4.
Insiderlista och lönsamhetsstatistik
Den här tabellen visar listan över kända insiders och genereras automatiskt från anmälningar som avslöjas till SEC. Förutom namnen, den senaste titeln och direktören, tjänstemannen eller ägarbeteckningen på 10 %, tillhandahåller vi de senaste avslöjade innehaven. Dessutom, när det är möjligt tillhandahåller vi insiderns historiska handelsresultat. Det historiska handelsresultatet är ett vägt genomsnitt av resultatet för faktiska köptransaktioner på den öppna marknaden som insidern gjort. För mer information om hur detta beräknas, titta på detta YouTube-webinarium.
See our leaderboard of most profitable insider traders.
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Nadim Ahmed President and CEO, Director - [D] [O] | 430 621 | 430 621 | |
|
Bvf Partners L P/il
10% Owner -
|
64 161 | 64 161 | |
| Patrick Baeuerle Chief Scientific Officer - [O] | 417 434 | 417 434 | |
| Thomas Ebeling Director - [D] | 186 653 | 186 653 | |
|
Bioscience I 2017 Ltd F2
10% Owner -
|
537 392 | 537 392 | |
|
F2 Gc, Llc
10% Owner -
|
104 762 | 104 762 | |
|
Vision SCS F2
10% Owner -
|
4 476 350 | 4 476 350 | |
| Mary Kay Fenton Chief Financial Officer - [O] | 60 000 | 60 000 |
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
|
Ansbert Gadicke
10% Owner -
|
595 489 | 595 489 | |
| Owen Hughes President and CEO, Director - [D] [O] | 506 226 | 506 226 | |
| Jeffrey Alan Jones Chief Medical Officer - [O] | 174 164 | 174 164 | |
|
Morana Jovan-Embiricos
10% Owner -
|
207 803 | 4 476 350 | |
| Raymond T Keane Chief Legal Officer - [O] | 24 124 | 24 124 | |
|
Mark N Lampert
10% Owner -
|
319 415 | 64 161 | |
|
MPM Oncology Impact Management LP
10% Owner -
|
7 648 268 | 7 648 268 | |
| Anne-Marie Martin | 36 880 | ||
| Jennifer Michaelson Chief Scientific Officer - [O] | 142 004 | 142 004 |
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Nate Nguyen Interim PAO and PFO - [O] | 13 375 | 13 375 | |
| Anthony Rosenberg Director - [D] | 45 002 | 45 002 | |
| Jacquelyn L Sumer Chief Legal Officer - [O] | 136 895 | 136 895 | |
| Corrine Savill Chief Business Officer - [O] | 240 990 | 240 990 | |
| Jeffrey Trigilio Chief Financial Officer - [O] | 133 919 | 133 919 | |
|
UBS Oncology Impact Fund L.P.
10% Owner -
|
7 648 268 | 7 648 268 | |
| Stephen W Webster | 7 800 | ||
| Jon Marc Wigginton | 116 666 | ||
| Leigh Zawel See Remarks - [O] | 69 785 | 69 785 |
Report errors via our new Insider Auditing Tool
Track Records av insiderköp - Kortsiktig vinstanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i CGEM / Cullinan Therapeutics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste köpen på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Track Records av insiderförsäljning - Kortsiktig förlustanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i CGEM / Cullinan Therapeutics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste försäljningarna på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Transaktionshistorik
Klicka på länkikonen för att se hela transaktionshistoriken. Transaktioner som rapporteras som en del av en automatisk handelsplan 10b5-1 kommer att ha ett X i kolumnen markerad 10b-5.
| Fil datum |
Handel datum |
Schema | Insider | Ticker | Värdepappertitel | Kod | Direkta | Utövningspris | Enhet pris |
Enheter ändrad |
Värde ändrad (1K) |
Kvarvarande Optioner |
Kvarvarande Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-27 | 2025-02-25 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 8,5300 | −3 756 | −32 | 142 004 | ||||
| 2025-02-27 | 2025-02-25 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 8,5300 | −3 756 | −32 | 136 895 | ||||
| 2025-02-27 | 2025-02-25 | 4 | AHMED NADIM | CGEM | Common Stock | D | 8,5300 | −12 529 | −107 | 430 621 | ||||
| 2025-02-27 | 2025-02-25 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 8,5300 | −4 895 | −42 | 174 164 | ||||
| 2025-02-21 | 2025-02-19 | 4 | Fenton Mary Kay | CGEM | Common Stock | D | 60 000 | 60 000 | ||||||
| 2025-02-21 | 2025-02-19 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 65 000 | 179 059 | ||||||
| 2025-02-21 | 2025-02-19 | 4 | AHMED NADIM | CGEM | Common Stock | D | 180 000 | 443 150 | ||||||
| 2025-02-21 | 2025-02-19 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 50 000 | 140 651 | ||||||
| 2025-02-21 | 2025-02-19 | 4 | Savill Corrine | CGEM | Common Stock | D | 37 500 | 240 990 | ||||||
| 2025-02-21 | 2025-02-19 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 50 000 | 145 760 | ||||||
| 2025-01-07 | 2025-01-06 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 12,5100 | −4 000 | −50 | 95 760 | ||||
| 2024-12-27 | 2024-12-24 | 4 | AHMED NADIM | CGEM | Common Stock | D | 11,8700 | −8 400 | −100 | 263 150 | ||||
| 2024-12-20 | 2024-12-18 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 11,4100 | −3 482 | −40 | 90 651 | ||||
| 2024-12-20 | 2024-12-18 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 11,4100 | −4 632 | −53 | 114 059 | ||||
| 2024-12-20 | 2024-12-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 11,4100 | −4 693 | −54 | 99 760 | ||||
| 2024-12-16 | 2024-12-12 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 12,5200 | −3 489 | −44 | 104 453 | ||||
| 2024-11-07 | 2024-11-05 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 15,6400 | −8 000 | −125 | 107 942 | ||||
| 2024-09-09 | 2024-09-05 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 18,0900 | −8 000 | −145 | 115 942 | ||||
| 2024-07-09 | 2024-07-05 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 16,3300 | −8 000 | −131 | 123 942 | ||||
| 2024-07-02 | 2024-07-01 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 9,0000 | 2 360 | 21 | 131 942 | ||||
| 2024-06-11 | 2024-06-10 | 4 | Ebeling Thomas | CGEM | Common Stock | D | 13,0000 | 18 450 | 240 | 186 653 | ||||
| 2024-05-23 | 2024-05-23 | 4 | Ebeling Thomas | CGEM | Common Stock | D | 12,7300 | 16 475 | 210 | 168 203 | ||||
| 2024-05-23 | 2024-05-23 | 4 | Ebeling Thomas | CGEM | Common Stock | D | 4,3000 | 84 224 | 362 | 151 728 | ||||
| 2024-05-08 | 2024-05-07 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 30,0600 | −5 606 | −169 | 129 582 | ||||
| 2024-05-08 | 2024-05-07 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 5 606 | 24 | 135 188 | ||||
| 2024-05-08 | 2024-05-06 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 28,5400 | −20 277 | −579 | 129 582 | ||||
| 2024-05-08 | 2024-05-06 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 27,8200 | −37 723 | −1 049 | 149 859 | ||||
| 2024-05-08 | 2024-05-06 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 50 000 | 215 | 187 582 | ||||
| 2024-04-02 | 3 | Nguyen Nate | CGEM | Common Stock | D | 13 375 | ||||||||
| 2024-04-02 | 3 | Nguyen Nate | CGEM | Common Stock | D | 13 375 | ||||||||
| 2024-04-02 | 3 | Nguyen Nate | CGEM | Common Stock | D | 6 250 | ||||||||
| 2024-02-23 | 2024-02-22 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 50 000 | 137 582 | ||||||
| 2024-02-23 | 2024-02-22 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 62 500 | 118 691 | ||||||
| 2024-02-23 | 2024-02-22 | 4 | AHMED NADIM | CGEM | Common Stock | D | 160 000 | 271 550 | ||||||
| 2024-02-23 | 2024-02-22 | 4 | Savill Corrine | CGEM | Common Stock | D | 37 500 | 203 490 | ||||||
| 2024-02-23 | 2024-02-22 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 50 000 | 94 133 | ||||||
| 2024-02-23 | 2024-02-22 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 50 000 | 133 919 | ||||||
| 2024-02-02 | 2024-02-01 | 4 | Savill Corrine | CGEM | Common Stock | D | 16,1800 | −40 000 | −647 | 165 990 | ||||
| 2024-02-02 | 2024-02-01 | 4 | Savill Corrine | CGEM | Common Stock | D | 4,3000 | 40 000 | 172 | 205 990 | ||||
| 2024-01-30 | 2024-01-29 | 4 | Savill Corrine | CGEM | Common Stock | D | 14,0900 | −40 000 | −564 | 165 990 | ||||
| 2024-01-30 | 2024-01-29 | 4 | Savill Corrine | CGEM | Common Stock | D | 4,3000 | 40 000 | 172 | 205 990 | ||||
| 2024-01-24 | 2024-01-23 | 4 | Savill Corrine | CGEM | Common Stock | D | 12,4600 | −21 316 | −266 | 165 990 | ||||
| 2024-01-24 | 2024-01-23 | 4 | Savill Corrine | CGEM | Common Stock | D | 4,3000 | 21 316 | 92 | 187 306 | ||||
| 2024-01-24 | 2024-01-22 | 4 | Savill Corrine | CGEM | Common Stock | D | 12,0200 | −4 125 | −50 | 165 990 | ||||
| 2024-01-24 | 2024-01-22 | 4 | Savill Corrine | CGEM | Common Stock | D | 12,1800 | −14 559 | −177 | 170 115 | ||||
| 2024-01-24 | 2024-01-22 | 4 | Savill Corrine | CGEM | Common Stock | D | 4,3000 | 14 559 | 63 | 184 674 | ||||
| 2023-12-27 | 2023-12-26 | 4 | AHMED NADIM | CGEM | Common Stock | D | 9,2400 | −4 272 | −39 | 111 550 | ||||
| 2023-12-22 | 2023-12-21 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 8,5000 | −1 400 | −12 | 44 133 | ||||
| 2023-12-22 | 2023-12-21 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 8,5000 | −1 860 | −16 | 56 191 | ||||
| 2023-12-22 | 2023-12-21 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 8,5000 | −1 920 | −16 | 83 919 | ||||
| 2023-12-22 | 2023-12-21 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 8,5000 | −1 145 | −10 | 87 582 | ||||
| 2023-12-20 | 2023-12-18 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 8,2200 | −290 | −2 | 45 533 | ||||
| 2023-12-20 | 2023-12-18 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 8,2200 | −398 | −3 | 85 839 | ||||
| 2023-12-20 | 2023-12-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 8,2200 | −238 | −2 | 88 727 | ||||
| 2023-12-20 | 2023-12-18 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 8,2200 | −386 | −3 | 58 051 | ||||
| 2023-12-13 | 2023-12-12 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 7,8100 | −1 068 | −8 | 88 965 | ||||
| 2023-12-13 | 2023-12-12 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 7,8100 | −1 926 | −15 | 86 237 | ||||
| 2023-07-05 | 2023-06-30 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 9,0800 | 2 340 | 21 | 88 163 | ||||
| 2023-06-29 | 2023-06-28 | 4 | AHMED NADIM | CGEM | Common Stock | D | 11,4000 | −759 | −9 | 115 822 | ||||
| 2023-06-21 | 2023-06-20 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 12,9400 | −399 | −5 | 85 823 | ||||
| 2023-06-21 | 2023-06-20 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 12,9400 | −291 | −4 | 45 823 | ||||
| 2023-06-21 | 2023-06-20 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 12,9400 | −238 | −3 | 90 033 | ||||
| 2023-06-21 | 2023-06-20 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 12,9400 | −387 | −5 | 58 437 | ||||
| 2023-06-14 | 2023-06-12 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 13,1100 | −176 | −2 | 90 271 | ||||
| 2023-06-14 | 2023-06-12 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 13,1100 | −319 | −4 | 86 222 | ||||
| 2023-06-08 | 2023-06-07 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 12,4000 | −100 | −1 | 90 447 | ||||
| 2023-06-08 | 2023-06-07 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 100 | 0 | 90 547 | ||||
| 2023-06-08 | 2023-06-06 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 12,3100 | −11 900 | −146 | 90 447 | ||||
| 2023-06-08 | 2023-06-06 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 11 900 | 51 | 102 347 | ||||
| 2023-05-24 | 2023-05-23 | 4 | AHMED NADIM | CGEM | Common Stock | D | 9,1500 | −707 | −6 | 116 581 | ||||
| 2023-05-19 | 2023-05-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 8,7600 | −239 | −2 | 90 447 | ||||
| 2023-05-19 | 2023-05-18 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 8,7600 | −394 | −3 | 58 824 | ||||
| 2023-05-19 | 2023-05-18 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 8,7600 | −399 | −3 | 86 541 | ||||
| 2023-05-19 | 2023-05-18 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 8,7600 | −291 | −3 | 46 114 | ||||
| 2023-05-16 | 2023-05-12 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 8,7800 | −193 | −2 | 90 686 | ||||
| 2023-05-16 | 2023-05-12 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 8,7800 | −347 | −3 | 86 940 | ||||
| 2023-04-26 | 2023-04-25 | 4 | AHMED NADIM | CGEM | Common Stock | D | 10,5900 | −716 | −8 | 117 288 | ||||
| 2023-04-20 | 2023-04-18 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 10,7100 | −392 | −4 | 59 218 | ||||
| 2023-04-20 | 2023-04-18 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 10,7100 | −398 | −4 | 87 287 | ||||
| 2023-04-20 | 2023-04-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 10,7100 | −238 | −3 | 90 879 | ||||
| 2023-04-20 | 2023-04-18 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 10,7100 | −290 | −3 | 46 405 | ||||
| 2023-04-14 | 2023-04-12 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 10,2200 | −318 | −3 | 87 685 | ||||
| 2023-04-14 | 2023-04-12 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 10,2200 | −176 | −2 | 91 117 | ||||
| 2023-03-27 | 2023-03-20 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 11,3200 | −238 | −3 | 91 293 | ||||
| 2023-03-27 | 2023-03-23 | 4 | AHMED NADIM | CGEM | Common Stock | D | 10,5100 | −706 | −7 | 118 004 | ||||
| 2023-03-27 | 2023-03-20 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 11,3200 | −390 | −4 | 59 610 | ||||
| 2023-03-27 | 2023-03-20 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 11,3200 | −305 | −3 | 46 695 | ||||
| 2023-03-27 | 2023-03-20 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 11,3200 | −399 | −5 | 88 003 | ||||
| 2023-02-23 | 2023-02-22 | 4 | AHMED NADIM | CGEM | Common Stock | D | 109 000 | 118 710 | ||||||
| 2023-02-21 | 2023-02-17 | 4 | Baeuerle Patrick | CGEM | Common Stock | D | 38 500 | 76 000 | ||||||
| 2023-02-21 | 2023-02-17 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 47 000 | 88 402 | ||||||
| 2023-02-21 | 2023-02-17 | 4 | SUMER JACQUELYN L | CGEM | Common Stock | D | 47 000 | 47 000 | ||||||
| 2023-02-21 | 2023-02-17 | 4 | Savill Corrine | CGEM | Common Stock | D | 20 500 | 170 115 | ||||||
| 2023-02-21 | 2023-02-17 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 38 500 | 91 531 | ||||||
| 2023-02-21 | 2023-02-17 | 4 | Jones Jeffrey Alan | CGEM | Common Stock | D | 60 000 | 60 000 | ||||||
| 2023-02-10 | 2021-12-21 | 5 | GADICKE ANSBERT | CGEM | Common Stock | D | 4,3000 | 350 938 | 1 509 | 595 489 | ||||
| 2023-01-19 | 2023-01-19 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | −300 000 | 64 161 | ||||||
| 2023-01-19 | 2023-01-19 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | −2 600 000 | 392 808 | ||||||
| 2023-01-19 | 2023-01-19 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | −3 500 000 | 558 854 | ||||||
| 2023-01-06 | 2022-12-30 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 8,9700 | 201 | 2 | 41 402 | ||||
| 2022-11-29 | 2022-11-25 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 13,3000 | −4 000 | −53 | 53 031 | ||||
| 2022-11-29 | 2022-11-25 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 4 000 | 17 | 57 031 | ||||
| 2022-09-29 | 2022-09-27 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 12,4000 | −4 000 | −50 | 53 031 | ||||
| 2022-09-29 | 2022-09-27 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 4 000 | 17 | 57 031 | ||||
| 2022-08-09 | 2022-08-08 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 15,0100 | −1 385 | −21 | 53 031 | ||||
| 2022-08-09 | 2022-08-08 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 1 385 | 6 | 54 416 | ||||
| 2022-08-04 | 2022-08-04 | 4 | F2 Vision SCS | CGEM | Common Stock | D | 14,3056 | −25 989 | −372 | 1 255 963 | ||||
| 2022-08-04 | 2022-08-03 | 4 | F2 Vision SCS | CGEM | Common Stock | D | 14,2367 | −19 129 | −272 | 1 281 952 | ||||
| 2022-08-04 | 2022-08-02 | 4 | F2 Vision SCS | CGEM | Common Stock | D | 14,0973 | −4 792 | −68 | 1 301 081 | ||||
| 2022-07-26 | 2022-07-25 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 14,5100 | −8 000 | −116 | 53 031 | ||||
| 2022-07-26 | 2022-07-25 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 8 000 | 34 | 61 031 | ||||
| 2022-07-21 | 2022-07-19 | 4 | Savill Corrine | CGEM | Common Stock | D | 15,2200 | −14 958 | −228 | 149 615 | ||||
| 2022-07-21 | 2022-07-18 | 4 | Savill Corrine | CGEM | Common Stock | D | 15,0600 | −5 042 | −76 | 164 573 | ||||
| 2022-07-12 | 2022-07-11 | 4 | Savill Corrine | CGEM | Common Stock | D | 13,8500 | −200 | −3 | 169 615 | ||||
| 2022-07-12 | 2022-07-11 | 4 | Savill Corrine | CGEM | Common Stock | D | 13,3300 | −39 800 | −531 | 169 815 | ||||
| 2022-07-05 | 2022-06-30 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 10,9000 | 1 620 | 18 | 53 031 | ||||
| 2022-07-05 | 2022-06-30 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 10,9000 | 1 451 | 16 | 41 201 | ||||
| 2022-07-05 | 2022-06-30 | 4 | AHMED NADIM | CGEM | Common Stock | D | 10,9000 | 1 620 | 18 | 9 710 | ||||
| 2022-06-28 | 2022-06-24 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | D | 13,3900 | −45 078 | −604 | 207 803 | ||||
| 2022-06-28 | 2022-06-24 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | D | 4,3000 | 35 529 | 153 | 252 881 | ||||
| 2022-06-28 | 2022-06-24 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | D | 4,3000 | 104 845 | 451 | 217 352 | ||||
| 2022-06-23 | 2022-06-23 | 4 | F2 Bioscience I 2017 Ltd | CGEM | Common Stock | D | 13,0036 | −29 631 | −385 | 537 392 | ||||
| 2022-06-23 | 2022-06-22 | 4 | F2 Bioscience I 2017 Ltd | CGEM | Common Stock | D | 12,7035 | −49 953 | −635 | 567 023 | ||||
| 2022-06-23 | 2022-06-21 | 4 | F2 Bioscience I 2017 Ltd | CGEM | Common Stock | D | 12,7662 | −22 319 | −285 | 616 976 | ||||
| 2022-06-07 | 2022-06-06 | 4 | AHMED NADIM | CGEM | Common Stock | D | 12,4000 | 8 090 | 100 | 8 090 | ||||
| 2022-06-03 | 2022-06-01 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 10,9994 | 44 746 | 492 | 364 161 | ||||
| 2022-06-03 | 2022-06-01 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 10,9994 | 301 009 | 3 311 | 2 992 808 | ||||
| 2022-06-03 | 2022-06-01 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 10,9994 | 405 641 | 4 462 | 4 058 854 | ||||
| 2022-05-16 | 2022-05-16 | 4 | F2 Vision SCS | CGEM | Common Stock | D | 11,2301 | −35 158 | −395 | 1 305 873 | ||||
| 2022-05-16 | 2022-05-13 | 4 | F2 Vision SCS | CGEM | Common Stock | D | 10,4810 | −34 189 | −358 | 1 341 031 | ||||
| 2022-05-16 | 2022-05-13 | 4 | F2 Vision SCS | CGEM | Common Stock | D | 9,9631 | −85 319 | −850 | 1 375 220 | ||||
| 2022-05-16 | 2022-05-12 | 4 | F2 Vision SCS | CGEM | Common Stock | D | 9,2497 | −264 072 | −2 443 | 1 460 539 | ||||
| 2022-05-16 | 2022-05-13 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 9,1350 | 17 744 | 162 | 319 415 | ||||
| 2022-05-16 | 2022-05-13 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 9,1350 | 38 558 | 352 | 2 691 799 | ||||
| 2022-05-16 | 2022-05-13 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 9,1350 | 53 598 | 490 | 3 653 213 | ||||
| 2022-05-16 | 2022-05-12 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 9,0600 | 457 001 | 4 140 | 2 653 241 | ||||
| 2022-05-16 | 2022-05-12 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 9,0600 | 542 999 | 4 920 | 3 599 615 | ||||
| 2022-04-05 | 2022-04-01 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 10,7499 | 9 402 | 101 | 2 196 240 | ||||
| 2022-04-05 | 2022-04-01 | 4 | BVF PARTNERS L P/IL | CGEM | Common Stock | D | 10,7499 | 266 598 | 2 866 | 3 056 616 | ||||
| 2022-03-25 | 2021-09-16 | 4 | Ebeling Thomas | CGEM | Stock Option (Right to Buy) | D | 28,80 | 7 800 | 7 800 | |||||
| 2022-03-25 | 2021-09-16 | 4 | Rosenberg Anthony | CGEM | Stock Option (Right to Buy) | D | 28,80 | 7 800 | 7 800 | |||||
| 2022-03-25 | 2021-09-16 | 4 | Webster Stephen W | CGEM | Stock Option (Right to Buy) | D | 28,80 | 7 800 | 7 800 | |||||
| 2022-03-25 | 2021-09-16 | 4 | Jovan-Embiricos Morana | CGEM | Stock Option (Right to Buy) | D | 28,80 | 7 800 | 7 800 | |||||
| 2022-03-25 | 2021-09-16 | 4 | GADICKE ANSBERT | CGEM | Stock Option (Right to Buy) | D | 28,80 | 7 800 | 7 800 | |||||
| 2022-03-07 | 2022-03-05 | 4 | AHMED NADIM | CGEM | Performance Stock Unit | D | 215 000 | 215 000 | ||||||
| 2022-03-02 | 2022-03-01 | 4 | Martin Anne-Marie | CGEM | Stock Option (Right to Buy) | D | 13,99 | 36 880 | 36 880 | |||||
| 2022-03-02 | 2022-02-28 | 4 | Jones Jeffrey Alan | CGEM | Stock Option (Right to Buy) | D | 14,34 | 215 000 | 215 000 | |||||
| 2022-02-15 | 2022-02-11 | 4 | Michaelson Jennifer | CGEM | Stock Option (Right to Buy) | D | 13,60 | 57 000 | 57 000 | |||||
| 2022-02-15 | 2022-02-11 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 28 500 | 51 411 | ||||||
| 2022-02-15 | 2022-02-11 | 4 | Keane Raymond T | CGEM | Stock Option (Right to Buy) | D | 13,60 | 45 000 | 45 000 | |||||
| 2022-02-15 | 2022-02-11 | 4 | Keane Raymond T | CGEM | Common Stock | D | 22 500 | 24 124 | ||||||
| 2022-02-15 | 2022-02-11 | 4 | Zawel Leigh | CGEM | Stock Option (Right to Buy) | D | 13,60 | 65 000 | 65 000 | |||||
| 2022-02-15 | 2022-02-11 | 4 | Zawel Leigh | CGEM | Common Stock | D | 32 500 | 69 785 | ||||||
| 2022-02-15 | 2022-02-11 | 4 | Baeuerle Patrick | CGEM | Stock Option (Right to Buy) | D | 13,60 | 75 000 | 75 000 | |||||
| 2022-02-15 | 2022-02-11 | 4 | Baeuerle Patrick | CGEM | Common Stock | D | 37 500 | 37 500 | ||||||
| 2022-02-15 | 2022-02-11 | 4 | Trigilio Jeffrey | CGEM | Stock Option (Right to Buy) | D | 13,60 | 75 000 | 75 000 | |||||
| 2022-02-15 | 2022-02-11 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 37 500 | 39 750 | ||||||
| 2022-02-15 | 2022-02-11 | 4 | Savill Corrine | CGEM | Stock Option (Right to Buy) | D | 13,60 | 33 000 | 33 000 | |||||
| 2022-02-15 | 2022-02-11 | 4 | Savill Corrine | CGEM | Common Stock | D | 16 500 | 209 615 | ||||||
| 2022-01-13 | 2022-01-11 | 4 | F2 Vision SCS | CGEM | Common Stock | D | −1 187 734 | 1 724 611 | ||||||
| 2022-01-10 | 3 | LAMPERT MARK N | CGEM | Common Stock | D | 2 790 018 | ||||||||
| 2022-01-10 | 3 | LAMPERT MARK N | CGEM | Common Stock | D | 2 186 838 | ||||||||
| 2022-01-10 | 3 | LAMPERT MARK N | CGEM | Common Stock | D | 301 671 | ||||||||
| 2021-10-20 | 2021-10-18 | 4 | AHMED NADIM | CGEM | Stock Option (Right to Buy) | D | 21,12 | 2 710 000 | 2 710 000 | |||||
| 2021-10-20 | 2021-10-18 | 4 | Michaelson Jennifer | CGEM | Stock Option (Right to Buy) | D | 4,30 | −4 000 | 217 978 | |||||
| 2021-10-20 | 2021-10-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 23,6100 | −400 | −9 | 22 911 | ||||
| 2021-10-20 | 2021-10-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 22,4000 | −204 | −5 | 23 311 | ||||
| 2021-10-20 | 2021-10-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 21,1000 | −3 396 | −72 | 23 515 | ||||
| 2021-10-20 | 2021-10-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 4 000 | 17 | 26 911 | ||||
| 2021-10-18 | 2021-10-15 | 4 | Zawel Leigh | CGEM | Common Stock | D | 25,0000 | −19 574 | −489 | 37 285 | ||||
| 2021-10-18 | 2021-10-15 | 4 | Trigilio Jeffrey | CGEM | Stock Option (Right to Buy) | D | 4,30 | −8 000 | 229 891 | |||||
| 2021-10-18 | 2021-10-15 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 25,0000 | −8 000 | −200 | 2 250 | ||||
| 2021-10-18 | 2021-10-15 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 4,3000 | 8 000 | 34 | 10 250 | ||||
| 2021-10-12 | 2021-10-07 | 4 | Zawel Leigh | CGEM | Common Stock | D | 25,0000 | −1 079 | −27 | 56 859 | ||||
| 2021-09-21 | 2021-09-20 | 4 | Michaelson Jennifer | CGEM | Stock Option (Right to Buy) | D | 4,30 | −4 000 | 221 978 | |||||
| 2021-09-21 | 2021-09-20 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 25,2000 | −800 | −20 | 22 911 | ||||
| 2021-09-21 | 2021-09-20 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 24,3400 | −3 200 | −78 | 23 711 | ||||
| 2021-09-21 | 2021-09-20 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 4 000 | 17 | 26 911 | ||||
| 2021-09-21 | 2021-09-20 | 4 | Zawel Leigh | CGEM | Common Stock | D | 25,1600 | −7 468 | −188 | 57 938 | ||||
| 2021-09-20 | 2021-09-16 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,0600 | −3 124 | −91 | 7 648 268 | ||||
| 2021-09-20 | 2021-09-16 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,0600 | −3 124 | −91 | 7 648 268 | ||||
| 2021-09-20 | 2021-09-16 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,0600 | −432 | −13 | 244 551 | ||||
| 2021-09-16 | 2021-09-15 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,1600 | −6 425 | −187 | 7 651 392 | ||||
| 2021-09-16 | 2021-09-14 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,1700 | −7 106 | −207 | 7 657 817 | ||||
| 2021-09-16 | 2021-09-15 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,1600 | −6 425 | −187 | 7 651 392 | ||||
| 2021-09-16 | 2021-09-15 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,1600 | −888 | −26 | 244 983 | ||||
| 2021-09-16 | 2021-09-14 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,1700 | −7 106 | −207 | 7 657 817 | ||||
| 2021-09-16 | 2021-09-14 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,1700 | −982 | −29 | 245 871 | ||||
| 2021-09-13 | 2021-09-13 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,1000 | −3 595 | −105 | 7 664 923 | ||||
| 2021-09-13 | 2021-09-10 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,0400 | −5 931 | −172 | 7 668 518 | ||||
| 2021-09-13 | 2021-09-09 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,3500 | −13 727 | −403 | 7 674 449 | ||||
| 2021-09-13 | 2021-09-13 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,1000 | −3 595 | −105 | 7 664 923 | ||||
| 2021-09-13 | 2021-09-13 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,1000 | −497 | −14 | 246 853 | ||||
| 2021-09-13 | 2021-09-10 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,0400 | −5 931 | −172 | 7 668 518 | ||||
| 2021-09-13 | 2021-09-10 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,0400 | −820 | −24 | 247 350 | ||||
| 2021-09-13 | 2021-09-09 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,3500 | −13 727 | −403 | 7 674 449 | ||||
| 2021-09-13 | 2021-09-09 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,3500 | −1 898 | −56 | 248 170 | ||||
| 2021-09-09 | 2021-09-08 | 4 | Baeuerle Patrick | CGEM | Stock Option (Right to Buy) | D | 4,30 | −11 000 | 240 114 | |||||
| 2021-09-09 | 2021-09-08 | 4 | Baeuerle Patrick | CGEM | Common Stock | D | 28,4500 | −11 000 | −313 | 0 | ||||
| 2021-09-09 | 2021-09-08 | 4 | Baeuerle Patrick | CGEM | Common Stock | D | 4,3000 | 11 000 | 47 | 11 000 | ||||
| 2021-09-09 | 2021-09-08 | 4 | Trigilio Jeffrey | CGEM | Stock Option (Right to Buy) | D | 4,30 | −15 000 | 237 891 | |||||
| 2021-09-09 | 2021-09-08 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 28,8500 | −9 513 | −274 | 2 250 | ||||
| 2021-09-09 | 2021-09-08 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 27,8300 | −5 487 | −153 | 11 763 | ||||
| 2021-09-09 | 2021-09-08 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 4,3000 | 15 000 | 64 | 17 250 | ||||
| 2021-09-08 | 2021-09-08 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,1100 | −10 842 | −316 | 7 688 176 | ||||
| 2021-09-08 | 2021-09-07 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,0400 | −25 067 | −728 | 7 699 018 | ||||
| 2021-09-08 | 2021-09-03 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,6000 | −12 731 | −377 | 7 724 085 | ||||
| 2021-09-08 | 2021-09-08 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,1100 | −10 842 | −316 | 7 688 176 | ||||
| 2021-09-08 | 2021-09-08 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,1100 | −1 499 | −44 | 250 068 | ||||
| 2021-09-08 | 2021-09-07 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,0400 | −25 067 | −728 | 7 699 018 | ||||
| 2021-09-08 | 2021-09-07 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,0400 | −3 465 | −101 | 251 567 | ||||
| 2021-09-08 | 2021-09-03 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,6000 | −12 731 | −377 | 7 724 085 | ||||
| 2021-09-08 | 2021-09-03 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,6000 | −1 760 | −52 | 255 032 | ||||
| 2021-09-08 | 2021-09-07 | 4 | Zawel Leigh | CGEM | Common Stock | D | 28,9500 | −28 118 | −814 | 65 406 | ||||
| 2021-09-02 | 2021-09-02 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,4600 | −15 757 | −464 | 7 736 816 | ||||
| 2021-09-02 | 2021-09-01 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,4700 | −5 714 | −168 | 7 752 573 | ||||
| 2021-09-02 | 2021-08-31 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 30,1400 | −1 553 | −47 | 7 758 287 | ||||
| 2021-09-02 | 2021-08-31 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,4300 | −1 285 | −38 | 7 759 840 | ||||
| 2021-09-02 | 2021-09-02 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,4600 | −15 757 | −464 | 7 736 816 | ||||
| 2021-09-02 | 2021-09-02 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,4600 | −2 178 | −64 | 256 792 | ||||
| 2021-09-02 | 2021-09-01 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,4700 | −5 714 | −168 | 7 752 573 | ||||
| 2021-09-02 | 2021-09-01 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,4700 | −790 | −23 | 258 970 | ||||
| 2021-09-02 | 2021-08-31 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 30,1400 | −1 553 | −47 | 7 758 287 | ||||
| 2021-09-02 | 2021-08-31 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 30,1400 | −215 | −6 | 259 760 | ||||
| 2021-09-02 | 2021-08-31 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,4300 | −1 285 | −38 | 7 759 840 | ||||
| 2021-09-02 | 2021-08-31 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,4300 | −177 | −5 | 259 975 | ||||
| 2021-08-31 | 2021-08-30 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,3000 | −31 001 | −908 | 7 761 125 | ||||
| 2021-08-31 | 2021-08-30 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,3000 | −4 285 | −126 | 260 152 | ||||
| 2021-08-31 | 2021-08-27 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,0900 | −13 357 | −389 | 7 792 126 | ||||
| 2021-08-31 | 2021-08-27 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,0900 | −1 846 | −54 | 264 437 | ||||
| 2021-08-31 | 2021-08-30 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,3000 | −31 001 | −908 | 7 761 125 | ||||
| 2021-08-31 | 2021-08-27 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,0900 | −13 357 | −389 | 7 792 126 | ||||
| 2021-08-26 | 2021-08-10 | 4/A | Zawel Leigh | CGEM | Common Stock | D | 28,4900 | −1 817 | −52 | 121 642 | ||||
| 2021-08-26 | 2021-08-10 | 4/A | Zawel Leigh | CGEM | Common Stock | D | 27,3400 | −3 191 | −87 | 123 459 | ||||
| 2021-08-26 | 2021-08-10 | 4/A | Zawel Leigh | CGEM | Common Stock | D | 26,5000 | −1 906 | −51 | 126 650 | ||||
| 2021-08-26 | 2021-08-09 | 4/A | Zawel Leigh | CGEM | Common Stock | D | 27,1100 | −1 700 | −46 | 128 556 | ||||
| 2021-08-26 | 2021-08-09 | 4/A | Zawel Leigh | CGEM | Common Stock | D | 26,5200 | −19 504 | −517 | 130 256 | ||||
| 2021-08-26 | 2021-08-23 | 4/A | Zawel Leigh | CGEM | Common Stock | D | 29,0000 | −28 118 | −815 | 93 524 | ||||
| 2021-08-26 | 2021-08-18 | 4/A | Michaelson Jennifer | CGEM | Stock Option (Right to Buy) | D | 4,30 | −4 000 | 225 978 | |||||
| 2021-08-26 | 2021-08-18 | 4/A | Michaelson Jennifer | CGEM | Common Stock | D | 28,0700 | −1 137 | −32 | 22 911 | ||||
| 2021-08-26 | 2021-08-18 | 4/A | Michaelson Jennifer | CGEM | Common Stock | D | 27,5000 | −2 863 | −79 | 24 048 | ||||
| 2021-08-26 | 2021-08-18 | 4/A | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 4 000 | 17 | 26 911 | ||||
| 2021-08-26 | 2021-08-10 | 4 | Baeuerle Patrick | CGEM | Stock Option (Right to Buy) | D | 4,30 | −11 000 | 251 114 | |||||
| 2021-08-26 | 2021-08-10 | 4 | Baeuerle Patrick | CGEM | Common Stock | D | 27,0000 | −11 000 | −297 | 0 | ||||
| 2021-08-26 | 2021-08-10 | 4 | Baeuerle Patrick | CGEM | Common Stock | D | 4,3000 | 11 000 | 47 | 11 000 | ||||
| 2021-08-25 | 2021-08-25 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,0900 | −1 713 | −50 | 7 805 483 | ||||
| 2021-08-25 | 2021-08-24 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,4800 | −50 822 | −1 498 | 7 807 196 | ||||
| 2021-08-25 | 2021-08-23 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,1100 | −53 359 | −1 553 | 7 858 018 | ||||
| 2021-08-25 | 2021-08-25 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,0900 | −1 713 | −50 | 7 805 483 | ||||
| 2021-08-25 | 2021-08-25 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,0900 | −237 | −7 | 266 283 | ||||
| 2021-08-25 | 2021-08-24 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,4800 | −50 882 | −1 500 | 7 807 196 | ||||
| 2021-08-25 | 2021-08-24 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,4800 | −7 025 | −207 | 266 520 | ||||
| 2021-08-25 | 2021-08-23 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,1100 | −53 359 | −1 553 | 7 858 018 | ||||
| 2021-08-25 | 2021-08-23 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,1100 | −7 376 | −215 | 273 545 | ||||
| 2021-08-24 | 2021-08-18 | 4 | Michaelson Jennifer | CGEM | Stock Option (Right to Buy) | D | 4,30 | −4 000 | 225 978 | |||||
| 2021-08-24 | 2021-08-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 28,0700 | −1 137 | −32 | 22 911 | ||||
| 2021-08-24 | 2021-08-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 27,5000 | −2 863 | −79 | 24 048 | ||||
| 2021-08-24 | 2021-08-18 | 4 | Michaelson Jennifer | CGEM | Common Stock | D | 4,3000 | 4 000 | 17 | 26 911 | ||||
| 2021-08-24 | 2021-08-23 | 4 | Zawel Leigh | CGEM | Common Stock | D | 29,0000 | −28 118 | −815 | 93 524 | ||||
| 2021-08-12 | 2021-08-11 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 29,0500 | −2 510 | −73 | 7 911 377 | ||||
| 2021-08-12 | 2021-08-11 | 4 | GADICKE ANSBERT | CGEM | Common Stock | I | 29,0500 | −2 510 | −73 | 7 911 377 | ||||
| 2021-08-12 | 2021-08-11 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 29,0500 | −347 | −10 | 280 921 | ||||
| 2021-08-11 | 2021-08-10 | 4 | Zawel Leigh | CGEM | Common Stock | D | 28,4900 | −1 817 | −52 | 121 642 | ||||
| 2021-08-11 | 2021-08-10 | 4 | Zawel Leigh | CGEM | Common Stock | D | 27,3400 | −3 191 | −87 | 123 459 | ||||
| 2021-08-11 | 2021-08-10 | 4 | Zawel Leigh | CGEM | Common Stock | D | 26,5000 | −1 906 | −51 | 126 650 | ||||
| 2021-08-11 | 2021-08-09 | 4 | Zawel Leigh | CGEM | Common Stock | D | 27,1100 | −1 700 | −46 | 128 556 | ||||
| 2021-08-11 | 2021-08-09 | 4 | Zawel Leigh | CGEM | Common Stock | D | 26,5200 | −19 504 | −517 | 130 256 | ||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Series C Convertible Preferred Stock | D | −649 030 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Series B Convertible Preferred Stock | D | −2 276 692 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Series A Convertible Preferred Stock | D | −3 551 640 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Series Seed Convertible Preferred Stock | D | −1 136 525 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 21,0000 | 300 000 | 6 300 | 7 913 887 | ||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 649 030 | 7 613 887 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 2 276 692 | 6 964 857 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 3 551 640 | 4 688 165 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | UBS Oncology Impact Fund L.P. | CGEM | Common Stock | D | 1 136 525 | 1 136 525 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Series C Convertible Preferred Stock | I | −649 030 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Series B Convertible Preferred Stock | I | −2 276 692 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Series A Convertible Preferred Stock | I | −3 551 640 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Series Seed Convertible Preferred Stock | I | −1 136 525 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Common Stock | I | 21,0000 | 300 000 | 6 300 | 7 913 887 | ||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Common Stock | I | 649 030 | 7 613 887 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Common Stock | I | 2 276 692 | 6 964 857 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Common Stock | I | 3 551 640 | 4 688 165 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | GADICKE ANSBERT See footnotes | CGEM | Common Stock | I | 1 136 525 | 1 136 525 | ||||||
| 2021-01-14 | 2021-01-07 | 4 | GADICKE ANSBERT | CGEM | Stock Option (Right to Buy) | D | 4,30 | 88 824 | 88 824 | |||||
| 2021-01-14 | 2021-01-07 | 4 | GADICKE ANSBERT | CGEM | Stock Option (Right to Buy) | D | 4,30 | 262 114 | 262 114 | |||||
| 2021-01-14 | 2021-01-07 | 4 | GADICKE ANSBERT See footnotes | CGEM | Series C Convertible Preferred Stock | I | 649 030 | 649 030 | ||||||
| 2021-01-14 | 2021-01-07 | 4 | GADICKE ANSBERT See footnotes | CGEM | Series B Convertible Preferred Stock | I | 2 276 692 | 2 276 692 | ||||||
| 2021-01-14 | 2021-01-07 | 4 | GADICKE ANSBERT See footnotes | CGEM | Series A Convertible Preferred Stock | I | 3 551 640 | 3 551 640 | ||||||
| 2021-01-14 | 2021-01-07 | 4 | GADICKE ANSBERT See footnotes | CGEM | Series Seed Convertible Preferred Stock | I | 1 136 525 | 1 136 525 | ||||||
| 2021-01-14 | 2021-01-07 | 4 | GADICKE ANSBERT | CGEM | Common Stock | D | 281 268 | 281 268 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series C Convertible Preferred Stock | I | −1 511 966 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series C Convertible Preferred Stock | I | −503 988 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series C Convertible Preferred Stock | I | −503 988 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series C Convertible Preferred Stock | I | −1 007 977 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series B Convertible Preferred Stock | I | −1 282 051 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series B Convertible Preferred Stock | I | −3 205 128 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series A Convertible Preferred Stock | I | −4 500 000 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series A Convertible Preferred Stock | I | −20 500 000 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Series Seed Convertible Preferred Stock | I | −8 000 000 | 0 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 21,0000 | 104 762 | 2 200 | 104 762 | ||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 21,0000 | 95 238 | 2 000 | 622 175 | ||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 214 798 | 214 798 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 71 599 | 71 599 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 71 599 | 71 599 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 143 198 | 325 333 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 182 135 | 182 135 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 455 338 | 455 338 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 639 295 | 639 295 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 2 912 345 | 2 912 345 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Jovan-Embiricos Morana | CGEM | Common Stock | I | 1 136 525 | 1 136 525 | ||||||
| 2021-01-14 | 2021-01-12 | 4 | Trigilio Jeffrey | CGEM | Common Stock | D | 21,0000 | 2 250 | 47 | 2 250 | ||||
| 2021-01-14 | 2021-01-12 | 4 | Hughes Owen | CGEM | Common Stock | D | 21,0000 | 2 500 | 52 | 506 226 | ||||
| 2021-01-11 | 2021-01-07 | 4 | Baeuerle Patrick | CGEM | Stock Option (Right to Buy) | D | 21,00 | 286 665 | 286 665 | |||||
| 2021-01-11 | 2021-01-07 | 4 | Zawel Leigh | CGEM | Stock Option (Right to Buy) | D | 21,00 | 56 666 | 56 666 | |||||
| 2021-01-11 | 2021-01-07 | 4 | Michaelson Jennifer | CGEM | Stock Option (Right to Buy) | D | 21,00 | 79 999 | 79 999 | |||||
| 2021-01-11 | 2021-01-07 | 4 | Hughes Owen | CGEM | Stock Option (Right to Buy) | D | 21,00 | 433 332 | 433 332 | |||||
| 2021-01-11 | 2021-01-07 | 4 | Trigilio Jeffrey | CGEM | Stock Option (Right to Buy) | D | 21,00 | 146 665 | 146 665 | |||||
| 2021-01-11 | 2021-01-07 | 4 | Wigginton Jon Marc | CGEM | Stock Option (Right to Buy) | D | 21,00 | 116 666 | 116 666 | |||||
| 2021-01-11 | 2021-01-07 | 4 | Keane Raymond T | CGEM | Stock Option (Right to Buy) | D | 21,00 | 249 998 | 249 998 | |||||
| 2021-01-07 | 3 | Michaelson Jennifer | CGEM | Common Stock | D | 22 911 | ||||||||
| 2021-01-07 | 3 | Rosenberg Anthony | CGEM | Common Stock | D | 45 002 | ||||||||
| 2021-01-07 | 3 | Ebeling Thomas | CGEM | Common Stock | D | 67 504 | ||||||||
| 2021-01-07 | 3 | Zawel Leigh | CGEM | Common Stock | D | 149 760 | ||||||||
| 2021-01-07 | 3 | GADICKE ANSBERT | CGEM | Common Stock | D | 281 268 | ||||||||
| 2021-01-07 | 3 | Baeuerle Patrick | CGEM | Common Stock | I | 341 434 | ||||||||
| 2021-01-07 | 3 | Keane Raymond T | CGEM | Common Stock | D | 1 624 | ||||||||
| 2021-01-07 | 3 | F2 MC, LLC | CGEM | Common Stock | D | 112 507 | ||||||||
| 2021-01-07 | 3 | Hughes Owen | CGEM | Common Stock | D | 503 726 | ||||||||
| 2021-01-07 | 3 | Savill Corrine | CGEM | Common Stock | D | 193 115 |
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)
